Jason Rhodes is a partner and focuses on creating and building novel therapeutics companies.

Jason is the chairman and was the founding CEO of Dyne Therapeutics (NASDAQ: DYN), Rectify Pharmaceuticals, and Generation Bio (NASDAQ: GBIO). He is also on the boards of AAVantgarde Bio, Be Biopharma, K36, and Accent Therapeutics. He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020, and was previously on the boards of Third Harmonic Bio (NASDAQ: THRD), and Replimune (NASDAQ: REPL).

Previously, Jason held leadership positions at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development, and Epizyme (NASDAQ: EPZM), where he was President and built the company from early stage research into the clinic and through a successful IPO in 2013. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer.

Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.

Jason spends his free time mountain biking and loudly watching Spanish fútbol with his family.